Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 14, 2016

Primary Completion Date

June 20, 2021

Study Completion Date

January 29, 2025

Conditions
Advanced Rare Tumours
Interventions
DRUG

Durvalumab

DRUG

Tremelimumab

Trial Locations (13)

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H4A 3J1

The Research Institute of the McGill University, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK